LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 22.93

Change

-0.42 (-1.80)%

Market Cap

N/A

Volume

500.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEQT:CA iShares Core Equity Portfolio

-0.48 (-1.37%)

CAD 6.91B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

CAD 6.63B
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.15 (-0.49%)

CAD 6.19B
PHYS-U:CA Sprott Physical Gold Trust

+0.25 (+1.00%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

-0.43 (-1.15%)

CAD 4.54B
ZMMK:CA BMO Money Market Fund ETF Seri..

+0.01 (+0.02%)

CAD 4.20B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.32 (+0.65%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

N/A

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

+0.12 (+1.08%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.10 (-0.44%)

CAD 2.78B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.09% 18% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.09% 17% F 19% F
Trailing 12 Months  
Capital Gain -10.29% 8% B- 15% F
Dividend Return 4.38% 85% B 79% B-
Total Return -5.91% 8% B- 16% F
Trailing 5 Years  
Capital Gain -4.85% 21% F 24% F
Dividend Return 33.22% 88% B+ 75% C
Total Return 28.36% 35% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 2.12% 43% F 42% F
Dividend Return 3.13% 46% F 38% F
Total Return 1.01% 79% B- 37% F
Risk Return Profile  
Volatility (Standard Deviation) 5.95% 74% C 88% B+
Risk Adjusted Return 52.66% 59% D- 63% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.